Tissue culture media supplemented with 10% fetal calf serum contains a castrate level of testosterone.
BACKGROUND
Human prostate cancer cells are routinely maintained in media supplemented with 10% Fetal Calf Serum (FCS) to provide androgen. In the present study, total and free testosterone levels in 10%FCS supplemented tissue culture media were determined and compared to levels in intact and castrated human males. Dextran-coated charcoal stripped FCS (i.e., DC-FCS) is often used instead of FCS to minimize the level of androgen provided in 10% serum supplemented media. Therefore, total and free testosterone levels in 10%DC-FCS containing media were likewise determined.


METHODS
Total testosterone, free testosterone, and total dihydrotestosterone (DHT) were determined on RPMI-1640 media supplemented with either 10%FCS or 10%DC-FCS by ELISA assays before and after exposure to LNCaP human prostate cancer cells in culture. The growth and PSA secretion by these cells was also determined.


RESULTS
Ten percentage FCS supplemented media contains a castrate level of testosterone. However, even with this castrate starting level of testosterone, LNCaP cells concentrate and metabolize the testosterone to produce a physiologic (i.e., 10 nM) level of intracellular DHT which optimally stimulates the growth of these cells in vitro.


CONCLUSIONS
The present studies document that prostate cancer cells auto-regulate their androgen metabolism so that an optimal level of DHT for growth is maintained during both up and down fluctuations in the supply of testosterone. These results have significant implications for whether exogenous androgen should be added to the 10%FCS supplemented media to grow prostate cancer cells from intact versus castrated patients.
Sedelaar
J P Michiel
JP
Department of Oncology, Sidney Kimmel Comprehensive Cancer Center, The Johns Hopkins University, School of Medicine, Baltimore, MD 21231, USA. m.sedelaar@uro.umcn.nl
Isaacs
John T
JT
D000818:Animals; D002369:Castration; D002417:Cattle / Q000196:embryology*; D002455:Cell Division; D002460:Cell Line; D002606:Charcoal; D003470:Culture Media / Q000737:chemistry*; D003911:Dextrans; D013196:Dihydrotestosterone / Q000032:analysis / Q000378:metabolism; D004797:Enzyme-Linked Immunosorbent Assay; D005312:Fetal Blood; D006706:Homeostasis; D006801:Humans; D008297:Male; D009994:Osmolar Concentration; D017430:Prostate-Specific Antigen; D011471:Prostatic Neoplasms / Q000378:metabolism* / Q000473:pathology; D013739:Testosterone / Q000032:analysis* / Q000378:metabolism
D003470:Culture Media; D003911:Dextrans; D013196:Dihydrotestosterone; D002606:Charcoal; D013739:Testosterone; D017430:Prostate-Specific Antigen
Can J Biochem. 1968 Apr;46(4):299-302
5690431
Theriogenology. 1979 Oct;12(4):223-33
16725448
Proc Natl Acad Sci U S A. 2006 Oct 10;103(41):15085-90
17015840
Clin Cancer Res. 2004 Nov 1;10(21):7121-6
15534082
Int J Urol. 2009 May;16(5):516-21
19389135
Prostate. 1992;21(1):15-34
1641369
Ann N Y Acad Sci. 2009 Feb;1155:33-42
19250190
Clin Cancer Res. 2006 Jul 1;12(13):4072-9
16818707
Can J Comp Med. 1972 Apr;36(2):94-8
4259937
Prostate. 1994 May;24(5):221-8
7513416
Steroids. 1975 Aug;26(2):227-32
171806
Endocr Relat Cancer. 2009 Jun;16(2):325-32
19240183
Clin Cancer Res. 2005 Jul 1;11(13):4653-7
16000557
Cancer Res. 2004 Jan 15;64(2):765-71
14744796
Endocr Rev. 2004 Dec;25(6):947-70
15583024
J Reprod Fertil. 1976 Jan;46(1):143-9
1271335
J Steroid Biochem. 1979 Jul;11(1B):631-6
491627
Clin Cancer Res. 2004 Jan 15;10(2):440-8
14760063
J Urol. 2008 Apr;179(4):1235-42
18280514
J Biochem. 1977 Jun;81(6):1721-31
408338
J Biol Chem. 2007 Aug 31;282(35):25801-16
17591767
J Urol. 2002 Sep;168(3):1001-4
12187208
Biol Reprod. 1978 Dec;19(5):1108-12
743545
Urology. 2000 Dec 20;56(6):1021-4
11113751
J Urol. 2005 Feb;173(2):342-59
15643172
Biol Reprod. 1973 Apr;8(3):277-82
4634002
J Urol. 2007 Oct;178(4 Pt 1):1290-5
17698136
Endocr Res Commun. 1976;3(1):71-82
1278092
J Urol. 2005 Feb;173(2):360-72
15643173
Cell Cycle. 2007 Mar 15;6(6):647-51
17387277